ΔNp73β is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria

Cell Cycle

Volumn 9, Issue 13, 2010, Pages 2629-2639

  Schuster, André ^a   Schilling, Tobias ^b   De Laurenzi, Vincenzo ^c   Koch, Andreas F ^a   Seitz, Sarah ^a   Staib, Frank ^d   Teufel, Andreas ^d   Thorgeirsson, Snorri S ^e   Galle, Peter R ^d   Melino, Gerry ^f,g   Stremmel, Wolfgang ^a   Krammer, Peter H ^h   Müller, Martina ^a  

^a Department of Internal Medicine IV   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e NATIONAL CANCER INSTITUTE   (United States)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Dominant negative p73; Hepatocellular carcinoma; p53 family; Therapy response

Indexed keywords

CASPASE 2; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; DEATH RECEPTOR; PROTEIN DELTANP73BETA; PROTEIN P53; PROTEIN P73; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MITOCHONDRION; NEGATIVE FEEDBACK; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; TRANSACTIVATION; UPREGULATION;

EID: 77955438760     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.13.12110     Document Type: Article

References (50)

1. Müller M, Schulze-Schleithoff E, Stremmel W, et al. One, two, three - p53, p63, p73 and chemosensitivity. Drug Resist Updat 2006; 9:288-306.
2. Vilgelm A, El Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat 2008; 11:152-63.
3. Vazquez A, Bond EE, Levine AJ, et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7:979-87.
4. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2:605-15.
5. Maisse C, Munarriz E, Barcaroli D, et al. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death Differ 2004; 11:685-7. (Pubitemid 38786716)
6. Rosenbluth JM, Pietenpol JA. The jury is in: p73 is a tumor suppressor after all. Genes Dev 2008; 22:2591-5.
7. Riley T, Sontag E, Chen P, et al. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12. (Pubitemid 351574202)
8. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
9. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13. (Pubitemid 29197649)
10. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8. (Pubitemid 29197650)
11. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103. (Pubitemid 30143141)
12. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-73. (Pubitemid 40544653)
13. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-76.
14. Müller M, Schilling T, Sayan AE, et al. TAp73/DeltaNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12:1564-77. (Pubitemid 41679162)
15. Seitz SJ, Schleithoff ES, Koch A, et al. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 2010; 126:2049-66.
16. Stiewe T, Zimmermann S, Frilling A, et al. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002; 62:3598-602.
17. Tannapfel A, John K, Mise N, et al. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 2008; 29:211-8. (Pubitemid 351201761)
18. Castillo J, Goni S, Latasa MU, et al. Amphiregulin Induces the Alternative Splicing of p73 Into Its Oncogenic Isoform DeltaEx2p73 in Human Hepatocellular Tumors. Gastroenterology 2009; 137:1805-15.
19. Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-13. (Pubitemid 27414797)
20. Gressner O, Schilling T, Lorenz K, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24:2458-71. (Pubitemid 41032596)
21. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9.
22. Nicoletti I, Migliorati G, Paggliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
23. Müller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188:2033-45. (Pubitemid 28562520)
24. Galluzzi L, Aaronson SA, Abrams J, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16:1093-107.
25. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40:667-76. (Pubitemid 39265589)
26. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12:410-6.
27. Kissil JL, Deiss LP, Bayewitch M, et al. Isolation of DAP3, a novel mediator of interferon-gamma-induced cell death. J Biol Chem 1995; 270:27932-6.
28. Kissil JL, Cohen O, Raveh T, et al. Structure-function analysis of an evolutionary conserved protein, DAP3, which mediates TNF-alpha- and Fas-induced cell death. EMBO J 1999; 18:353-62. (Pubitemid 29041944)
29. Miyazaki T, Reed JC. A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins. Nat Immunol 2001; 2:493-500. (Pubitemid 33705850)
30. Kim HR, Chae HJ, Thomas M, et al. Mammalian dap3 is an essential gene required for mitochondrial homeostasis in vivo and contributing to the extrinsic pathway for apoptosis. FASEB J 2007; 21:188-96. (Pubitemid 46052556)
31. Schilling T, Schleithoff ES, Kairat A, et al. Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem Biophys Res Commun 2009; 387:399-404.
32. Dominguez G, Garcia JM, Pena C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53 and E2F-1. J Clin Oncol 2006; 24:805-15. (Pubitemid 46622048)
33. Zaika AI, Slade N, Erster SH, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in human tumors. J Exp Med 2002; 196:765-80.
34. Casciano I, Mazzocco K, Boni L, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9:246-51. (Pubitemid 34223868)
35. Faridoni-Laurens L, Tourpin S, Alsafadi S, et al. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Cell Cycle 2008; 7:1587-96. (Pubitemid 351881326)
36. Stiewe T, Tuve S, Peter M, et al. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10:626-33. (Pubitemid 38174002)
37. Petrenko O, Zaika A, Moll UM. DNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 2003; 23:5540-55. (Pubitemid 36957905)
38. Liu X, Yue P, Khuri FR, et al. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004; 64:5078-83. (Pubitemid 39006522)
39. Wu GS, Burns TF, McDonald ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene [letter]. Nat Genet 1997; 17:141-3.
40. Borrelli S, Candi E, Alotto D, et al. p63 regulates the caspase-8-FLIP apoptotic pathway in epidermis. Cell Death Differ 2009; 16:253-63.
41. Gupta S, Radha V, Furukawa Y, et al. Direct transcriptional activation of human caspase-1 by tumor suppressor p53. J Biol Chem 2001; 276:10585-8. (Pubitemid 38089225)
42. Yang C, Kaushal V, Haun RS, et al. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ 2008; 15:530-44. (Pubitemid 351267304)
43. Liedtke C, Groger N, Manns MP, et al. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be upregulated by a p53-dependent mechanism. J Biol Chem 2003; 278:27593-604. (Pubitemid 36899945)
44. Fortin A, Cregan SP, MacLaurin JG, et al. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J Cell Biol 2001; 155:207-16.
45. El-Deiry WS, Kern SE, Pietenpol JA, et al. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.
46. Perez CA, Ott J, Mays DJ, et al. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene 2007; 26:7363-70.
47. Vilgelm A, Wei JX, Piazuelo MB, et al. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene 2008; 27:2170-6.
48. Tomasini R, Tsuchihara K, Tsuda C, et al. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci USA 2009; 106:797-802.
49. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008; 18:244-52.
50. Vernole P, Neale MH, Barcaroli D et al. TAp73alpha binds the kinetochore proteins Bub1 and Bub3 resulting in polyploidy. Cell Cycle 2009; 8:421-9.